R

Renovaro Biosciences Inc
NASDAQ:RENB

Watchlist Manager
Renovaro Biosciences Inc
NASDAQ:RENB
Watchlist
Price: 1.266 USD Market Closed
Market Cap: 29.3m USD

Renovaro Biosciences Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Renovaro Biosciences Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
R
Renovaro Biosciences Inc
NASDAQ:RENB
Cash from Operating Activities
-$8.5m
CAGR 3-Years
31%
CAGR 5-Years
4%
CAGR 10-Years
-9%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$20.9B
CAGR 3-Years
-3%
CAGR 5-Years
5%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$9.7B
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$13.1B
CAGR 3-Years
10%
CAGR 5-Years
4%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.7B
CAGR 3-Years
-3%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$5.1B
CAGR 3-Years
-4%
CAGR 5-Years
18%
CAGR 10-Years
15%
No Stocks Found

Renovaro Biosciences Inc
Glance View

Market Cap
29.3m USD
Industry
Biotechnology

Enochian Biosciences, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. The company is headquartered in Los Angeles, California and currently employs 11 full-time employees. The company went IPO on 2014-11-18. The company is focused on developing allogeneic cell and gene therapies to promote stronger immune system responses for long-term or life-long cancer remission in cancers and to treat or cure infectious diseases, such as Human Immunodeficiency Virus (HIV) and Hepatitis B virus (HBV) infection. The Allogeneic Cell Therapy platform has a human immune system, which is designed to recognize the self and destroy otherness or non-self, such as bacteria, viruses and cancer cells. Its product candidates include ENOB-HV-01, which utilizes a cellular- and immunotherapy approach that could provide both preventative and therapeutic vaccines for HIV and ENOB-DC-11, which is a genetically modified allogeneic dendritic cell therapeutic vaccine as product for long-term remission of solid tumors. The company is also exploring ENOB-HV-21, a treatment for HIV with allogeneic natural killer and gamma delta t-cells.

RENB Intrinsic Value
0.07 USD
Overvaluation 94%
Intrinsic Value
Price
R

See Also

What is Renovaro Biosciences Inc's Cash from Operating Activities?
Cash from Operating Activities
-8.5m USD

Based on the financial report for Mar 31, 2025, Renovaro Biosciences Inc's Cash from Operating Activities amounts to -8.5m USD.

What is Renovaro Biosciences Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-9%

Over the last year, the Cash from Operating Activities growth was 21%. The average annual Cash from Operating Activities growth rates for Renovaro Biosciences Inc have been 31% over the past three years , 4% over the past five years , and -9% over the past ten years .

Back to Top